Profile data is unavailable for this security.
About the company
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
- Revenue in CAD (TTM)0.00
- Net income in CAD-110.00k
- Incorporated2009
- Employees--
- LocationVaxil Bio Ltd3400 One First Canadian PlaceTORONTO M5X 1A4CanadaCAN
- Websitehttps://vaxil-bio.com/
Mergers & acquisitions
Acquired company | VXL:CVE since announced | Transaction value |
---|---|---|
Copper Bullet Mines Inc | -50.00% | -- |